Mary-Ann Davies1,2, Tom Connell3,4, Christine Johannisen1, Kathryn Wood1,4, Sandy Pienaar1, Katalin A Wilkinson4,5, Robert J Wilkinson4,5,6, Heather J Zar1, Brian Eley1, David Beatty1, Nigel Curtis3, Mark P Nicol1,4. 1. Red Cross Children's Hospital and School of Child and Adolescent Health, University of Cape Town, Cape Town, South Africa. 2. School of Public Health and Family Medicine, University of Cape Town, South Africa. 3. Department of Paediatrics, University of Melbourne; Infectious Diseases Unit, Department of General Medicine; and Murdoch Children's Research Institute; Royal Children's Hospital Melbourne, Parkville, Australia. 4. Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa. 5. National Institute for Medical Research, Mill Hill, London NW7 1AA, UK. 6. Division of Medicine, Imperial College London, W2 1PG, UK.
Abstract
OBJECTIVE: To evaluate an enzyme-linked immunospot assay (ELISPOT) for the diagnosis of tuberculosis (TB) in HIV-infected children with suspected TB and to compare the performance of ELISPOT with the tuberculin skin test (TST). METHODS: Interferon-gamma responses to Mycobacterium tuberculosis-specific antigens were measured by ELISPOT in HIV-infected children with suspected TB. HIV-infected and HIV-uninfected children without TB were taken for comparison. RESULTS: Results were available for 188 children, of whom 139 (74%) were HIV-infected. Of these, 22 were classified as having definite TB: 24 probable TB, 14 possible TB and 128 not having TB. The median (range) age of patients was 20 (10-54.1) months. Median interferon-gamma responses to early-secreted antigenic target-6 and culture filtrate protein-10 were higher in children with definite or probable TB compared with children without TB (P < 0.002). In HIV-infected children with an interpretable ELISPOT result, the ELISPOT was positive in 14/21 (66%) with definite TB. A significantly higher proportion of HIV-infected children with definite or probable TB had a positive ELISPOT compared with a positive TST [25/39 (64%) vs. 10/34 (29%), P = 0.005]. In contrast to TST, results from ELISPOT were not affected by young age or severe immunosuppression. In HIV-infected children without active TB disease, 27% had a positive ELISPOT, suggesting latent TB infection. CONCLUSION: ELISPOT is more sensitive than TST for the detection of active TB in HIV-infected children. However, the sensitivity of current ELISPOT assays is not sufficiently high to be used as a rule out test for TB.
OBJECTIVE: To evaluate an enzyme-linked immunospot assay (ELISPOT) for the diagnosis of tuberculosis (TB) in HIV-infected children with suspected TB and to compare the performance of ELISPOT with the tuberculin skin test (TST). METHODS: Interferon-gamma responses to Mycobacterium tuberculosis-specific antigens were measured by ELISPOT in HIV-infected children with suspected TB. HIV-infected and HIV-uninfected children without TB were taken for comparison. RESULTS: Results were available for 188 children, of whom 139 (74%) were HIV-infected. Of these, 22 were classified as having definite TB: 24 probable TB, 14 possible TB and 128 not having TB. The median (range) age of patients was 20 (10-54.1) months. Median interferon-gamma responses to early-secreted antigenic target-6 and culture filtrate protein-10 were higher in children with definite or probable TB compared with children without TB (P < 0.002). In HIV-infected children with an interpretable ELISPOT result, the ELISPOT was positive in 14/21 (66%) with definite TB. A significantly higher proportion of HIV-infected children with definite or probable TB had a positive ELISPOT compared with a positive TST [25/39 (64%) vs. 10/34 (29%), P = 0.005]. In contrast to TST, results from ELISPOT were not affected by young age or severe immunosuppression. In HIV-infected children without active TB disease, 27% had a positive ELISPOT, suggesting latent TB infection. CONCLUSION: ELISPOT is more sensitive than TST for the detection of active TB in HIV-infected children. However, the sensitivity of current ELISPOT assays is not sufficiently high to be used as a rule out test for TB.
Authors: Annette Fox; David J Jeffries; Philip C Hill; Abdulrahman S Hammond; Moses D Lugos; Dolly Jackson-Sillah; Simon A Donkor; Patrick K Owiafe; Keith P W J McAdam; Roger H Brookes Journal: Trans R Soc Trop Med Hyg Date: 2007-04-16 Impact factor: 2.184
Authors: M P Nicol; D Pienaar; K Wood; B Eley; R J Wilkinson; H Henderson; L Smith; S Samodien; D Beatty Journal: Clin Infect Dis Date: 2005-03-23 Impact factor: 9.079
Authors: H Rabie; A Violari; T Duong; S A Madhi; D Josipovic; S Innes; E Dobbels; E Lazarus; R Panchia; A G Babiker; D M Gibb; M F Cotton Journal: Int J Tuberc Lung Dis Date: 2011-09 Impact factor: 2.373
Authors: E Chiappini; A Lo Vecchio; S Garazzino; G L Marseglia; F Bernardi; E Castagnola; P Tomà; D Cirillo; C Russo; C Gabiano; D Ciofi; G Losurdo; M Bocchino; E Tortoli; M Tadolini; A Villani; A Guarino; S Esposito Journal: Eur J Clin Microbiol Infect Dis Date: 2016-01 Impact factor: 3.267
Authors: Tom G Connell; Mary-Ann Davies; Christine Johannisen; Kathryn Wood; Sandy Pienaar; Katalin A Wilkinson; Robert J Wilkinson; Heather J Zar; David Beatty; Mark P Nicol; Nigel Curtis; Brian Eley Journal: BMC Infect Dis Date: 2010-05-27 Impact factor: 3.090
Authors: M X Rangaka; H P Gideon; K A Wilkinson; M Pai; J Mwansa-Kambafwile; G Maartens; J R Glynn; A Boulle; K Fielding; R Goliath; R Titus; S Mathee; R J Wilkinson Journal: Eur Respir J Date: 2011-06-30 Impact factor: 16.671
Authors: Rokeya Sultana Rekha; S M Mostafa Kamal; Peter Andersen; Zeaur Rahim; Md Imranul Hoq; Gul Ara; Jan Andersson; David Sack; Rubhana Raqib Journal: PLoS One Date: 2011-01-21 Impact factor: 3.240